Fighting to push its $8 billion acquisition of Grail past European regulators, Illumina suffered a key setback Wednesday when an EU court ruled an antitrust probe into the buyout can proceed.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,